NUVB supply chain intelligence for Nuvation Bio Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we ob… |
| AZN | AstraZeneca PLC | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we ob… |
| BMY | Bristol-Myers Squibb Company | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we … |
| BMYMP | Bristol-Myers Squibb Co | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from REGN graph: Reciprocal relationship from NUVB graph: t of our investigational products. … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| SNYNF | Sanofi | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| EISAI | EISAI | 92% | In addition, Eisai is required to pay to the Company certain tiered royalties at rates in the low- to high-teens on aggregate annual net sales of licensed products during the applicable royalty term,… |
| SAGARD-HOLDINGS | SAGARD-HOLDINGS | 85% | ng supply, build out of additional commercial infrastructure, substantial investment and significant marketing efforts, before we generate any revenue from product sales. We are not permitted to mark… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we ob… |
| AZN | AstraZeneca PLC | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from BMY graph: Reciprocal relationship from NUVB graph: t of our investigational products. We… |
| BMY | Bristol-Myers Squibb Company | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we … |
| BMYMP | Bristol-Myers Squibb Co | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we o… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| SNYNF | Sanofi | 72% | t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from SNYN… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NUVB-DEBT | Debt stack $217.0M | 90% | Market cache reports total debt of $217.0M. |
| NUVB-DEBT-11416 | Warrants outstanding: 5787472 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| NUVB-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 234 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 2 | ['customer', 'supplier'] |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | ['customer', 'supplier'] |
| DNTH | Dianthus Therapeutics, Inc. | 100.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | ['customer', 'supplier'] |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| LLY | Eli Lilly and Company | 100.00 | 2 | |
| XNCR | Xencor, Inc. | 100.00 | 2 | |
| BHC | Bausch Health Companies Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 2 | ['customer', 'supplier'] |
| VRDN | Viridian Therapeutics, Inc. | 100.00 | 2 | |
| EISAI | EISAI | 63.48 | 1 | ['receiving'] |
| ALNY | Alnylam Pharmaceuticals, Inc. | 50.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| ALLR | Allarity Therapeutics, Inc. | 50.00 | 2 | |
| RGNX | REGENXBIO Inc. | 50.00 | 2 | |
| TBPH | Theravance Biopharma, Inc. | 50.00 | 2 | |
| CELU | Celularity Inc. | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 |